ApexOnco Front Page Recent articles 14 March 2025 Sutro calls time on folate At long last luvelta-T is shelved, and Sutro seeks a new focus. 13 March 2025 Ono takes on Takeda in polycythemia vera The Japanese group licenses sapablursen from Ionis for $280m. 27 November 2024 Nerviano becomes a targeted PARP player Two cast-offs comprise the private group's attempts to hit PARP1 and PARP7. 26 November 2024 Roche doubles down on Poseida A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders. 25 November 2024 Truqap could fill a prostate cancer gap The AKT inhibitor prevails in hormone-sensitive disease, but other studies have been delayed. 22 November 2024 Targeted lung cancer niche sees a German pharma battle But could toxicity be holding back filing plans? 21 November 2024 Kyowa buys into menin, but it's not Syndax's Syndax scored the first menin approval, but Kura is first with a licensing deal. 20 November 2024 Genmab formalises the challenge against its partner GEN1286/PRO1286 features among the latest industry projects to enter clinical trials. Load More Recent Quick take Another Epkinly lymphoma combo goes pivotal 22 July 2024 Caribou puts another nail in the Car-NK coffin 17 July 2024 Sotio builds a presence in antibody conjugates 17 July 2024 The SHP2 ship sails 17 July 2024 In vivo Car-T heads for the clinic, but it’s not Sana’s 15 July 2024 Keros challenges Geron 15 July 2024 Merus goes into phase 3 12 July 2024 Roche declares KRAS war on Amgen and Bristol 12 July 2024 Ipsen makes its second cautious conjugate move 11 July 2024 ADC player Baili to go public in a different guise 11 July 2024 Load More Most Popular